Goldman Sachs Downgrades AccoTest to Neutral: Gains Realized, Awaiting New Product Volume Growth

Overview

In its latest report, Goldman Sachs downgraded AccoTest (688200.SS) from Buy to Neutral, maintaining the target price at 354 Yuan unchanged. The report notes that while the company benefits long-term from rising capital expenditure in China's semiconductor equipment and domestic substitution trends in testing equipment, it faces short-term challenges including slowing consumer electronics demand, slower-than-expected volume ramp of new product STS8600, and current share price fully reflecting future growth expectations.

Core views

Demand Side: Consumer electronics end-market demand remains weak, and rising memory prices have suppressed shipment growth for STS8300. Q1 2026 revenue was 26% below expectation, mainly due to constrained demand for traditional consumer electronics test equipment. Supply Side: The next-generation testing platform STS8600 is expected to accelerate volume ramp-up in 2027-2028, but contribution remains limited in the short term. The company continues to increase R&D investment; R&D headcount grew 28% YoY to 486 people in 2025, leading to an increase in the R&D expense ratio. Profit Forecast: Based on revenue downward revisions and increased expense ratio, net profit forecasts for 2026-2027 are cut by 13% and 11% respectively. Nevertheless, net profit is still projected to maintain a CAGR of 24%-33% from 2026 to 2028. Valuation Level: Maintaining the target price of 354 Yuan based on a 2027 P/E of 55.5x (up from previous 49.5x). Current valuation sits between the 5-year historical mean and +1 standard deviation, reflecting that the market has already priced in long-term growth expectations quite sufficiently.

Analysis framework

The report adopts relative valuation methods, determining target PE through peer comparison. Specific method: Select comparable companies, establish a regression relationship between trading P/E and YoY net profit growth for the next year, thereby deriving the reasonable valuation multiple for AccoTest. Regarding profit forecasts, bottom-up approaches are used, splitting revenue for STS8300 and STS8600 product lines separately. Combined with gross margin assumptions and expense ratio forecasts, future three-year profit forecasts are derived. In scenario analysis, the report explicitly lists three key variables: scale of China WFE capital expenditure, domestic substitution rate of semiconductor test equipment, intensity of market competition, as follow-up tracking priorities.

Methodology notes

• Valuation MethodPE/PEG valuation

  Peer P/E Comparison Method

  Determine individual stock reasonable valuation multiples by comparing linear relationships between industry peers' P/E ratios and earnings growth rates. The report uses this method to set AccoTest's 2027 target P/E at 55.5x.

• Industry/Industrial Analysis FrameworkSupply-demand framework

  Volume-Price Breakdown

  Break down company revenue into shipment volumes and unit prices for each product line, predicting impacts on revenue from changes in demand side (consumer electronics, AI chips) and supply side (new product volume ramp pace) separately.

• Company Fundamentals and Financial FrameworkProfit Quality Analysis

  Expense Ratio and R&D Investment

  Assess the intensity of company investment during new product cycles by analyzing changes in R&D expense ratio, and adjust profit forecasts accordingly.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• AccoTest (688200.SS)

  Core Holding, Rating Downgraded to Neutral

  Strengths

  Benefits from Rising China WFE CapEx, Testing Equipment Domestic Substitution, AI Chip Testing Demand Growth

  Weaknesses

  Short-term Impacted by Weak Consumer Electronics Demand, New Product Volume Ramp Pace Slower than Expected

  Risks

  China WFE CapEx Lower than Expected, Slowing Domestic Substitution Process, Intensified Market Competition

Key data

• 2026 Net Profit Forecast691 Million CNYDown 13% from prior forecast
• 2027 Net Profit Forecast860 Million CNYDown 11% from prior forecast
• 2026-2028 Net Profit CAGR24%-33%Despite profit forecast cuts, high growth maintained
• Target P/E55.5xCorresponding to 2027 earnings, up from prior 49.5x
• Current Market Cap47.4 Billion CNYApproximately $6.9 Billion

Impact & implications

The report believes AccoTest's long-term growth logic remains valid: sustained rise in China's semiconductor equipment capital expenditure, accelerated domestic substitution of testing equipment, and expansion of AI chip testing demand. However, in the short term, weak consumer electronics demand and slower-than-expected new product ramp-up will constrain performance. For investors, current share price fully reflects growth expectations for the next two years, lacking obvious catalysts in the short term. Subsequent focus areas include: 1) Actual volume ramp-up of STS8600 in 2027-2028; 2) When consumer electronics end-demand bottoms out and rebounds; 3) Whether valuation regains attractiveness due to market sentiment fluctuations.

Risks

• China Semiconductor Equipment CapEx Higher/Lower than Expected
• Semiconductor Testing Equipment Domestic Substitution Rate Higher/Lower than Expected
• Market Competition Intensity Stronger/Weaker than Expected

What to watch

• Whether STS8600 Shipments Exceed Expectations
• Recovery Speed of Consumer Electronics End-Demand
• Whether Valuation Becomes Attractive Again